T22 as a free ligand exists in 1 entry. Examples include: 3G0B

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC18 H21 N5 O2
Molecular Weight339.39
Isomeric SMILESCn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O

Chemical Details

Formal Charge0
Atom Count46
Chiral Atom Count1
Chiral AtomsC11
Bond Count48
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB06203 Different stereochemistry
DescriptionAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
  • Alogliptina
  • Alogliptine
  • Alogliptinum
  • SYR-322
SaltsAlogliptin Benzoate
Brand Names
  • Alogliptin
  • Alogliptin and Metformin Hydrochloride
  • Alogliptin and Pioglitazone
  • Kazano
  • Nesina
Affected OrganismHumans and other mammals
IndicationIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacologyPeak inhibition of DPP-4 occurs within 2-3 hours after a single-dose administration to healthy subjects. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Alogliptin also demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an 8-hour period following a standardized meal. Alogliptin does not affect the QTc interval.
Mechanism of actionAlogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
Route of administrationOral
  • Alimentary Tract and Metabolism
  • Blood Glucose Lowering Agents
  • Blood Glucose Lowering Drugs, Excl. Insulins
  • Chemical Actions and Uses
  • Cytochrome P-450 CYP2D6 Substrates
  • A10BD13
  • A10BD09
  • A10BH04
CAS number850649-61-5

Drug Targets

NameSequence SearchPharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682